DUBLIN–(BUSINESS WIRE)–The “Global Allergy Diagnostics Market Size, Share, Growth Analysis, By Product & Service, By Test Type – Industry Forecast 2022-2028” report has been added to ResearchAndMarkets.com’s offering.
Global Allergy Diagnostics Market was valued at USD 4.80 billion in 2021, and the market size is estimated to reach USD 10.03 billion by 2028, at a CAGR of 11.10% over the forecast period (2022-2028).
It is anticipated that the market for allergy diagnostics would grow as pollution levels rise. Allergen exposure, occupational exposure, and exposure to both indoor and outdoor air pollution are the key risk factors for chronic respiratory illnesses. City inhabitants are more likely than rural dwellers to suffer from allergy diseases because of their higher exposure to pollution. The market for allergy diagnostics is anticipated to develop in response to the rise in food allergies.
Food allergies are a type of allergic illness that are more prevalent in urban areas and first-world nations than in rural areas and third-world nations. Two of the most obvious contrasts between these places are the level of cleanliness and the likelihood of infectious diseases.
It’s possible that early exposure to bacterial, viral, and parasite illnesses will have an impact on how the immune system develops. The incidence of sensitive skin and its propensity for irritation are on the rise, which can be attributed to factors such as climate change, air pollution, and the complexity of materials and cosmetics. In the near future, these elements are anticipated to propel the market for allergy diagnostics to expansion.
Driver
Exposure to both indoor and outdoor air pollution, allergies, and occupational exposure are the key risk factors for chronic respiratory illnesses. The prevalence of allergy diseases is higher in the urban population than in the rural population due to the higher exposure to environmental contaminants in cities (as a result of vehicular pollution and industrial activities).
While this is a global trend, the effects are most severe in low-income nations’ metropolitan centres. The WHO estimates that more than 80% of people who live in urban areas are exposed to air quality levels that exceed WHO safety recommendations. While air pollution from automobiles has been identified as a major risk factor for allergic disorders, this is an important indicator for the growth of the allergy diagnostics industry.
Restraint
Luminometers, blot analyzers, scanners, ELISA analyzers, and immunoassay analyzers are just a few of the allergy diagnostic equipment that go through routine updates from industry participants. These instruments cost extra since they offer a wide range of features and functions (the price of each instrument varies based on its accuracy, flexibility, and TAT).
For instance, luminometers range in price from $3,000 to $4,000, while immunoassay analyzers are priced between $10,000 and $20,000. Price ranges for semi-automatic ELISA readers range from US$ 2,000 to US$ 5,000, while US$ 14,000 is the starting price for fully automated analyzers. In addition, running this equipment comes with expenses for maintenance and insurance, lab supervision, and overheads (such as rent, office space, and administrative fees).
Market Trends
In order to lower the high cost of allergy diagnostics, reagent leasing agreements are becoming more popular. Contracts for the leasing of reagents are sales agreements between producers of allergy diagnostic products and purchasers (such as hospitals and diagnostic laboratories). In accordance with these contracts, the end user enters into a reagent-purchase agreement with the manufacturer and rents or purchases instruments at a discounted price.
This win-win arrangement lowers the end user’s initial capital outlay while guaranteeing the manufacturer long-term orders. Analyzers may occasionally be hired to end customers on a per-test basis. Laboratories can significantly reduce costs by using cost-per-test and reagent leasing contracts.
They aid labs in avoiding significant fixed capital expenditures related to the purchase of new equipment. As comparison to standard laboratories, these expenditures are much higher in high-volume laboratories. Also, since a contract typically lasts between 5 and 10 years, laboratories may stay current with the most recent developments in allergy diagnosis. Some contracts include service and maintenance fees in the total price, giving labs an additional financial advantage.
A selection of companies mentioned in this report includes
Thermo Fisher Scientific Inc., (US)
Siemens Healthineers (Germany)
Danaher (US)
Omega Diagnostics Group PLC (UK)
BioMerieux SA (France)
Romer Labs Division Holding (Austria)
EUROIMMUN Medizinische Labordiagnostika AG (Germany)
HollisterStier Allergy (US)
NEOGEN Corporation (US)
Minaris Medical America, Inc. (US)
Stallergenes Greer (UK)
HOB Biotech Group Corp., Ltd. (China)
HYCOR Biomedical (US)
R-Biopharm AG (Germany)
AESKU.GROUP GmbH (Germany)
ACON Laboratories, Inc. (US)
For more information about this report visit https://www.researchandmarkets.com/r/o5xxjo
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
